Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Travel Med ; 26(8)2019 Dec 23.
Artigo em Inglês | MEDLINE | ID: mdl-31355414

RESUMO

BACKGROUND: We conducted a comprehensive investigation to update our knowledge of traveler's diarrhea (TD) etiology and antimicrobial resistance (AMR) in Nepal. METHODS: A case-control study of TD etiology was conducted at the CIWEC Clinic Travel Medicine Center in Kathmandu from 2012 to 2014. Stool samples were tested by microscopy, culture and molecular techniques for identification of bacterial, viral and parasitic enteric pathogens, and AMR. We analysed patient demographic data, pre-treatment information and clinical outcomes. RESULTS: We enrolled 433 TD cases and 209 non-diarrhea controls. At least one of enteric pathogens was identified among 82% of cases and 44% of controls (P < 0.001). Multiple pathogens were observed among 35% of cases and 10% of controls. The most common pathogens significantly identified among cases in comparison with controls were Campylobacter (20%), norovirus (17%), enterotoxigenic E. coli (ETEC) (12%), rotavirus (9%) and Shigella (8%) (P < 0.001). We noted Campylobacter, Shigella and ETEC resistance to azithromycin at 8, 39 and 22% and to ciprofloxacin at 97, 78 and 23%, respectively. CONCLUSION: Among travellers to Nepal with TD, viral pathogens were commonly found and norovirus was the second most common pathogen after campylobacter. We noted increased AMR to fluoroquinolones (FQs) and azithromycin (AZM). There is heightened concern for AZM treatment failures, though this continues to remain the drug of choice for TD treatment in our setting where FQs should not be used.


Assuntos
Diarreia/diagnóstico , Resistência Microbiana a Medicamentos , Medicina de Viagem/métodos , Viagem , Adolescente , Adulto , Anti-Infecciosos/uso terapêutico , Azitromicina/uso terapêutico , Campylobacter/isolamento & purificação , Estudos de Casos e Controles , Diarreia/tratamento farmacológico , Diarreia/microbiologia , Escherichia coli/isolamento & purificação , Feminino , Fluoroquinolonas/uso terapêutico , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Nepal , Norovirus/isolamento & purificação , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA